Q4 2024 Bioventus Inc Earnings Call Transcript

Mar 11, 2025 / 12:30PM GMT

Transcript 10-K8-K

Key Points

Positve

Bioventus Inc (BVS) reported a strong financial performance in 2024, with double-digit organic revenue growth in all four quarters.
The company achieved a 14% revenue growth in the fourth quarter, driven by strong performance in surgical solutions and pain treatments.
Bioventus Inc (BVS) successfully divested its advanced rehabilitation business, optimizing its global portfolio.
The company paid down nearly $50 million in debt in the fourth quarter, improving its liquidity position.
Bioventus Inc (BVS) expanded its adjusted EBITDA margin by 160 basis points, demonstrating improved profitability.

Negative

The company faces challenges in maintaining growth in its restorative therapies segment, with sales being flat compared to the prior year.
Bioventus Inc (BVS) anticipates a headwind in the first quarter of 2025 due to higher year-end orders by certain distributors in the previous quarter.
The company expects its adjusted EBITDA to be lower in the first half of 2025 compared to the prior year due to the timing of growth investments.
Bioventus Inc (BVS) acknowledges that its international expansion will require more time and effort than initially anticipated.
The company faces competitive pressures in the pain treatments market, particularly in pricing strategies.

Operator

Good morning and welcome to the Bioventus fourth-quarter 2024 earnings conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Dave Crawford, Vice President, Investor Relations and Treasurer. Please go ahead.

Dave Crawford Bioventus Inc.;Vice President

Investor Relations and Treasurer

Thanks, Drew. And good morning, everyone, and thanks for joining us. It is my pleasure to welcome you to the Bioventus 2024 fourth-quarter earnings conference call. With me this morning are Rob Claypoole, President and CEO, and Mark Singleton, Senior Vice President and CFO. Rob will begin his remarks with an update on our business and lay out our 2025 priorities. Mark will provide detail on our fourth-quarter results and discuss our 2025 financial guidance, and we will finish the call with Q&A. The presentation for today's call is available on the investors section of our website bioventus.com.

But before we begin, I would like to remind everyone that our remarks today contain

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.